TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02728843
Drug: Deferiprone
Normalized name: Deferiprone
DrugBank: Deferiprone (DB08826)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 600 mg tablets
Study: NCT02826226
Drug: Bronchodilator Agents
Normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00333216
Drug: Anecortave Acetate Sterile Suspension, 30 mg/mL
DrugBank: Anecortave acetate (DB05288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posterior juxtascleral administration of suspension
Study: NCT00333216
Drug: Anecortave Acetate Sterile Suspension, 60 mg/ML
DrugBank: Anecortave acetate (DB05288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posterior juxtascleral administration of suspension
Study: NCT01956305
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin 500mg tablet for Cohort F
Study: NCT01413490
Drug: rimantadine
Normalized name: Rimantadine
DrugBank: Rimantadine (DB00478)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12 weeks of rimantadine therapy in addition to standard combination therapy with interferon and ribavirin
Study: NCT01676831
Drug: Topical resiquimod 0.06%
DrugBank: Resiquimod (DB06530)
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical resiquimod 0.06% dosing frequency begins at 3 times per week and evaluated every two weeks. Will be applied for a total of 8 weeks followed by 4 weeks rest and then followed by another 8 weeks of application with another 4 weeks rest.
Study: NCT01676831
Drug: topical resiquimod 0.03%
DrugBank: Resiquimod (DB06530)
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical resiquimod 0.03% applied initially 5 times weekly for 8 weeks with adjustments up or down based upon tolerability followed by 4 weeks rest followed by another 8 weeks of treatment followed by another 4 week rest period.
Study: NCT01364064
Drug: TMZ
Normalized name: TMZ
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Comparing conventional adjuvant Temozolomide with dose intensive Temozolomide
Study: NCT03196765
Drug: Sobetirome (NV1205)
Normalized name: Sobetirome
DrugBank: Sobetirome (DB07425)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once a day oral dose of the study drug
Study: NCT00090012
Drug: Olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00090012
Drug: Quetiapine
Normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00125554
Drug: Metyrapone
Normalized name: Metyrapone
DrugBank: Metyrapone (DB01011)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00999830
Drug: IPH2101
DrugBank: IPH 2101 (DB06049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One infusion of IPH2101 every 4 weeks
Study: NCT00522210
Drug: Detemir
Normalized name: Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will discontinue their usual bedtime dose of intermediate acting insulin and replace this with the same unit dose of detemir at supper time. The detemir will not be mixed with the rapid acting insulin and will be given as a separate injection. The patient's morning dose of intermediate acting insulin will be decreased by 20% to adjust for the longer duration of action of detemir. Doses of rapid acting insulin will remain the same at breakfast and at supper.
Study: NCT01343706
Drug: BI 409306
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release solid oral dosage (film-coated tablet)
Study: NCT01343706
Drug: BI 409306
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: solution for oral administration
Study: NCT00003200
Drug: Taxotere
Normalized name: Taxotere
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02376413
Drug: Chemotherapy or endocrine therapy or Trastuzumab therapy
Normalized name: Monistat Simple Therapy
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02103686
Drug: Lyrica
Normalized name: Lyrica
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00412256
Drug: Omegaven (10% fish-oil emulsion; Fresenius-Kabi)
Normalized name: Omegaven
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00138216
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00138216
Drug: temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00138216
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04781075
Drug: Bupivacaine Injection
Normalized name: bupivacaine Injection
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given at the beginning of the surgery for post-operative pain management
Study: NCT02562625
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Powder solution for infusion
Study: NCT03124459
Drug: ACE-083
Normalized name: albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1 - Recombinant fusion protein. Part 2 - Recombinant fusion protein or buffer solution.
Study: NCT00282243
Drug: tacrolimus modified release (MR)
Normalized name: tacrolimus Extended Release Oral Tablet
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral
Study: NCT00282243
Drug: tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral
Study: NCT03453892
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The normal clinical treatment-plan of the underlying disease remains unchanged.
Study: NCT03453892
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The normal clinical treatment-plan of the underlying disease remains unchanged.
Study: NCT03453892
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The normal clinical treatment-plan of the underlying disease remains unchanged.
Study: NCT00317044
Drug: Esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Esomeprazole 40 mg twice daily
Study: NCT00317044
Drug: Esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Esomeprazole 40 mg once daily
Study: NCT00851903
Drug: Insulin Glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous injection. 100 Units/mL solution for injection in a prefilled SoloStar® pen (3 mL).
Study: NCT00851903
Drug: Sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral administration. 100mg film-coated tablets.
Study: NCT00851903
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients continued with metformin as usual oral anti-diabetic treatment.
Study: NCT00430118
Drug: asparaginase
Normalized name: Asparaginase
DrugBank: Asparaginase Escherichia coli (DB00023)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00430118
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00430118
Drug: daunorubicin hydrochloride
Normalized name: Daunorubicin Hydrochloride
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00430118
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00430118
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00430118
Drug: ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00430118
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00430118
Drug: thioguanine
Normalized name: Thioguanine
DrugBank: Tioguanine (DB00352)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00430118
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00430118
Drug: vindesine
Normalized name: vindesine
DrugBank: Vindesine (DB00309)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00270894
Drug: epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: epirubicin (100 mg/m\^2) every 2 weeks for 4 cycles
Study: NCT00270894
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel (75 mg/m\^2) every 2 weeks for 4 cycles
Study: NCT00270894
Drug: trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: trastuzumab (6 mg/kg \[loading dose\] once then 4 mg/kg \[maintenance dose\]) every 2 weeks for 4 treatments
Study: NCT00320970
Drug: Candesartan
Normalized name: Candesartan
DrugBank: Candesartan (DB13919)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04647110
Drug: crizotinib
Normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: as provided in real world practice
Study: NCT04647110
Drug: alectinib
Normalized name: Alectinib
DrugBank: Alectinib (DB11363)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: as provided in real world practice
Study: NCT04647110
Drug: brigatinib
Normalized name: Brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: as provided in real world practice
Study: NCT04647110
Drug: ceritinib
Normalized name: Ceritinib
DrugBank: Ceritinib (DB09063)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: as provided in real world practice
Study: NCT04647110
Drug: lorlatinib
Normalized name: LORLATINIB
DrugBank: Lorlatinib (DB12130)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: as provided in real world practice
Study: NCT02811744
Drug: 11C-acetate
Normalized name: 11C-ACETATE
DrugBank: Acetic acid C-11 (DB15111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive injection of radioactive tracer 11C-acetate and complete a PET/CT scan.
Study: NCT03642184
Drug: Empagliflozin
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dosage adjustment based on glucose targets . Once daily
Study: NCT03642184
Drug: Linagliptin
Normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dosage adjustment based on glucose targets. Once daily
Study: NCT00260208
Drug: Cyclosporine A
Normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial dose of 10-15mg/kg/day either orally, via a nasogastric (NG) tube or intravenously (i.v.) within the first 24 hours post-transplantation.
Study: NCT00260208
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus was administered within the first 24 hours post-transplantation at an initial dose of 0.1-0.15 mg/kg/day in 2 divided doses either orally or via a nasogastric (NG) tube or intravenously (i.v).
Study: NCT01070329
Drug: Duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants received 30 milligrams (mg) duloxetine once daily (QD) by mouth (po) for 1 week, followed by 60 mg QD po for 7 weeks. Participants were given the option to take duloxetine 30 mg QD, po for a 2-week taper phase.
Study: NCT02154646
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered IV
Study: NCT03576144
Drug: BI 1265162
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple rising inhaled doses
Study: NCT02318095
Drug: Gemcitabine/nab-Paclitaxel
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prospective, single arm study ; eligible subjects will recieve 2 cycles of neoadjuvant Gemcitabine/nab-Paclitaxel. All chemotherapy administered to study subjects is standard of care. The chemotherapy combination, gemcitabine/nab-paclitaxel, is considered to be a standard-of-care, non-investigational chemotherapy combination; chemotherapy dosing and treatment schedule will be managed by the treating medical oncologist. Restaging will be completed post chemotherapy.
Study: NCT00686127
Drug: Lidoderm patch
Normalized name: lidocaine Medicated Patch [Lidoderm]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 patch was applied topically to the affected site(s) for 12 hours each day.
Study: NCT01552057
Drug: Duloxetine 60 mg
Normalized name: duloxetine 60 MG
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Duloxetine 60 mg taken orally once every day for 15 weeks
Study: NCT01045954
Drug: Lispro Insulin and glargine insulin
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Continuous glucose sensor will be inserted. Subject will be on an isocaloric diet and CGM downloaded daily. Insulin basal and bolus will be adjusted based upon treatment goals until goals reached
Study: NCT00972465
Drug: Nimotuzumab and chemotherapy
Normalized name: cytarabine and daunorubicin
DrugBank: Nimotuzumab (DB06192)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental: Nimotuzumab and Irinotecan~the chemotherapy treatment: Irinotecan (180 mg/m2/time, 1 time/14 days, until disease progression)~the nimotuzumab treatment: 3 levels (200 mg/w, 400 mg/w, 600 mg/w, weekly, until disease progression)
Study: NCT00286052
Drug: Low Dose Naloxone
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00358657
Drug: Fludarabine Phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00358657
Drug: Mycophenolate Mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT00358657
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT00358657
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV or PO
Study: NCT01835184
Drug: cabozantinib-s-malate
Normalized name: Cabozantinib S-Malate
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT01835184
Drug: vemurafenib
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00701493
Drug: Topiramate oral liquid formulation;Topiramate Sprinkle formulation
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01085318
Drug: Rebif
Normalized name: Rebif
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 44 mcg tiw
Study: NCT00039767
Drug: Lepirudin
Normalized name: Lepirudin
DrugBank: Lepirudin (DB00001)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00460382
Drug: raltegravir potassium
Normalized name: Raltegravir Potassium
DrugBank: Raltegravir (DB06817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 400 mg twice a day
Study: NCT00460382
Drug: darunavir/ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2 pills of 300 mg twice a day
Study: NCT00460382
Drug: etravirine
Normalized name: Etravirine
DrugBank: Etravirine (DB06414)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 2 pills of 100 mg twice a day
Study: NCT01381055
Drug: Pentoxifylline
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients with cutaneous leishmaniasis treated with pentavalent antimony/Meglumine antimoniate 20mg/kg/day during 20 days and pentoxifylline pills 400mg three times a day during 20 days.
Study: NCT00928070
Drug: Fesoterodine
Normalized name: Fesoterodine
DrugBank: Fesoterodine (DB06702)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fesoterodine 4 mg and 8 mg
Study: NCT02479347
Drug: Chlorhexidine
Normalized name: Chlorhexidine
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative skin preparation with tinted chlorhexidine gluconate 2% in 70% isopropyl alcohol administered with single-dose applicator
Study: NCT02479347
Drug: Povidone-Iodine
Normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative skin preparation with povidone-iodine 10% aqueous solution
Study: NCT01562028
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be treated with erlotinib, 150 mg p.o., daily
Study: NCT01562028
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will be treated with bevacizumab 15 mg/kg i.v. on day 1 of each 3-week cycle (+/- 3 days)
Study: NCT01849926
Drug: Mecillinam
Normalized name: Mecillinam
DrugBank: Amdinocillin (DB01163)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01082276
Drug: Lurasidone HCl
Normalized name: lurasidone HCl
DrugBank: Lurasidone (DB08815)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40mg, Single-dose of lurasidone 40 mg (one 40 mg tablet) on Day 1. Daily dosing of rifampin 600 mg (two 300 mg capsules) on Days 1-8. On Day 8, subjects will also receive a single-dose of lurasidone 40 mg (one 40 mg tablet).
Study: NCT03448744
Drug: Thymosin Alpha1
Normalized name: Thymosin alpha1 (human)
DrugBank: Thymalfasin (DB04900)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymosin Alpha1 (1.6 mg subcutaneously injection twice a week) plus ETV (0.5 mg orally, daily) for 24 weeks, and followed by continuous ETV for at least 48 weeks
Study: NCT03448744
Drug: Entecavir
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ETV (0.5 mg orally, daily) for 72 weeks
Study: NCT02752828
Drug: Insulin glargine/lixisenatide (HOE901/AVE0010)
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study: NCT02752828
Drug: Insulin glargine (HOE901)
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study: NCT00412529
Drug: Entecavir
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Entecavir 0.5 mg once daily for 12 weeks.
Study: NCT00412529
Drug: Telbivudine
Normalized name: Telbivudine
DrugBank: Telbivudine (DB01265)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Telbivudine 600 mg once daily for 12 weeks.
Study: NCT01769911
Drug: carmustine
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01769911
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01769911
Drug: melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01769911
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01769911
Drug: O6-benzylguanine
Normalized name: O6-benzylguanine
DrugBank: 6-O-benzylguanine (DB11919)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT03763786
Drug: Cetrorelix Acetate
Normalized name: Cetrorelix Acetate
DrugBank: Cetrorelix (DB00050)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Used a standard
Study: NCT01492673
Drug: Cyclophosphamide, Topotecan, and Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The treatment schedule for this study will consist of a 21-day cycle. Dose modification will only occur with administration of the investigational agent, bevacizumab. The schedule of administration is summarized as follows. Administration of bevacizumab will precede the administration of the cyclophosphamide and topotecan by 3 days (Day - 3) to allow for vascular stabilization prior to initiation of chemotherapy. The chemotherapy backbone will consist of cyclophosphamide and topotecan administered as follows: cyclophosphamide 250 mg/m2/day IV over 30 minutes ± 5 minutes on Days 0-4 followed by topotecan 0.75 mg/m2/day IV over 30 minutes ± 5 minutes on Day 0-4 of every cycle. The dosing of cyclophosphamide and topotecan will be fixed.
Study: NCT00212043
Drug: carboplatin and gemcitabine
Normalized name: Carboplatin
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00001676
Drug: SQ Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03228368
Drug: Atezolizumab (MPDL3280A)
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: anti-programmed death-ligand 1 (PD-L1) antibody
Study: NCT04212000
Drug: Levoketoconazole
Normalized name: LEVOKETOCONAZOLE
DrugBank: Levoketoconazole (DB05667)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levoketoconazole tablet
Study: NCT04212000
Drug: Ketoconazole
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoconazole tablet
Study: NCT02786901
Drug: Loteprednol Etabonate Ophthalmic Gel dosed TID
Normalized name: loteprednol etabonate Ophthalmic Gel
DrugBank: Loteprednol etabonate (DB14596)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gel
Study: NCT02786901
Drug: Loteprednol Etabonate Ophthalmic Gel dosed BID
Normalized name: loteprednol etabonate Ophthalmic Gel
DrugBank: Loteprednol etabonate (DB14596)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gel
Study: NCT00763009
Drug: dipyridamole
Normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.28mg/kg over 4 minutes intravenously x three doses; totalling 0.84mg/kg intravenously
Study: NCT02557087
Drug: Hyoscine
Normalized name: Hyoscine
DrugBank: Scopolamine (DB00747)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02557087
Drug: Pethidine
Normalized name: Pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04345419
Drug: Remdesivir
Normalized name: remdesivir
DrugBank: Remdesivir (DB14761)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remdesivir as antiviral drug
Study: NCT00292084
Drug: Celgosivir
Normalized name: Celgosivir
DrugBank: Celgosivir (DB06580)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00382837
Drug: Epratuzumab
Normalized name: Epratuzumab
DrugBank: Epratuzumab (DB04958)
Approvals — FDA: no, EMA: no, PMDA: no